Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulmatrix Inc PULM

Healthcare
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as... see more

Recent & Breaking News (NDAQ:PULM)

Technical Reports on Biotech Equities -- Amicus Therapeutics, Pulmatrix, Amgen, and Bioverativ

PR Newswire July 17, 2017

Amit D. Munshi Joins Pulmatrix's Board of Directors

PR Newswire June 15, 2017

Pulmatrix Licenses Novel Drug Candidates from RespiVert Ltd., a wholly owned subsidiary of Janssen Biotech, Inc.

PR Newswire June 13, 2017

Technical Reports on Biotech Equities -- Amgen, Pulmatrix, Argos Therapeutics, and Bioverativ

PR Newswire June 13, 2017

Pulmatrix Receives Key US Patent for its Inhaled Drug for COPD

PR Newswire May 9, 2017

Pulmatrix Reports Q1 2017 Financial Results

PR Newswire May 5, 2017

Pulmatrix Appoints Ted Raad, MBA, as Chief Business Officer

PR Newswire May 3, 2017

Pulmatrix Adds Two Top Fungal Infection Experts to its Scientific Advisory Board

PR Newswire March 27, 2017

15 Biggest Mid-Day Losers For Thursday

Benzinga.com  March 23, 2017

15 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  March 22, 2017

Mid-Afternoon Market Update: Crude Oil Down 1.5%; Canadian Solar Shares Drop On Earnings Miss

Benzinga.com  March 21, 2017

Mid-Day Market Update: Dow Falls 150 Points; Pulmatrix Shares Spike Higher

Benzinga.com  March 21, 2017

Pulmatrix Receives European Patent for its Inhaled Drug Delivery Technology

PR Newswire March 21, 2017

15 Biggest Mid-Day Losers For Monday

Benzinga.com  March 20, 2017

A Peek Into The Markets: U.S. Stock Futures Edge Lower; Crude Oil Drops

Benzinga.com  March 20, 2017

15 Biggest Mid-Day Gainers For Friday

Benzinga.com  March 17, 2017

22 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  March 16, 2017

Pulmatrix Reports 2016 Financial Results; Provides 2017 Outlook on Pulmonary Disease Pipeline

PR Newswire March 10, 2017

Technical Reports on Biotech Stocks -- Bioverativ, Pulmatrix, PharmAthene, and Zosano Pharma

PR Newswire March 10, 2017

Trump's Intentions to Streamline Drug-Approval Process Fueling Biotech Optimism

PR Newswire Europe Non Regulatory February 7, 2017